Physician profile
Peter Roytman
NPI 1407885155
$2,766.53
in general payments reported to CMS, 2019-2025
19 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $281 · 2021: $346 · 2022: $461 · 2023: $620 · 2024: $178 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $590.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $443.28 | 2019-2024 | Xarelto |
| Pfizer INC. | $360.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $351.38 | 2019-2024 | Dificid, Recarbrio, Zerbaxa |
| Allergan, INC. | $203.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $162.44 | 2019-2025 | Eliquis, Camzyos |
| Abbvie INC. | $152.88 | 2021-2023 | Ubrelvy, Qulipta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.45 | 2019-2025 | Lifevest |
| Medtronic, INC. | $69.87 | 2022 | |
| Boston Scientific Corporation | $60.19 | 2020 | |
| Gilead Sciences, INC. | $57.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $53.48 | 2019-2020 | |
| Amgen INC. | $44.35 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $40.76 | 2019 | |
| Fisher & Paykel Healthcare INC | $29.31 | 2023 | Fisher & Paykel Healthcare |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $18.79 | 2025 | Arikayce |
| Kestra Medical Technology Services, INC. | $17.11 | 2024 | Assure Wcd |
| Ucb, INC. | $13.64 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Roytman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.